Cargando…
How does the efficacy and safety of Oralair(®) compare to other products on the market?
Due to differences between allergen immunotherapy (AIT) trials in patient populations, trial design (including primary efficacy variables), the definition of a pollen season, data analysis, and comparisons between AIT products with existing data, is not possible nor valid. The efficacy of two grass...
Autor principal: | Larenas-Linnemann, Désirée |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892828/ https://www.ncbi.nlm.nih.gov/pubmed/27313458 http://dx.doi.org/10.2147/TCRM.S70363 |
Ejemplares similares
-
Update about Oralair® as a treatment for grass pollen allergic rhinitis
por: Klimek, L., et al.
Publicado: (2022) -
156 Economic Evaluation of Grass Tablets for Immunotherapy (oralair) Compared to Placebo in Adults and Children in Italy
por: Cicchetti, Amerigo, et al.
Publicado: (2012) -
ARIA México 2014: transculturization of a guideline involving 11 national medical societies
por: Larenas-Linnemann, Désirée
Publicado: (2015) -
How an online survey on the treatment of allergic rhinitis and its impact on asthma (ARIA) detected specialty-specific knowledge-gaps
por: Larenas Linnemann, Désirée ES, et al.
Publicado: (2015) -
Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index
por: Daley-Yates, Peter T, et al.
Publicado: (2021)